Aptose’s Triple Drug AML Therapy Shows Promise in Phase 1/2 Trial
Aptose Biosciences reported promising early results from its Phase 1/2 TUSCANY trial, testing a triplet therapy of tuspetinib, venetoclax,...
Ati-2138: Potent, Selective Inhibitor of ITK and JAK3
Aclaris Therapeutics announced the publication of research on ATI-2138, a novel dual inhibitor of ITK and JAK3, currently in...
Tasso’s Patient-Centric Dried Blood Spot Technology
Tasso, a leader in patient-centric blood collection, launched its next-generation dried blood spot (DBS) sample collection system. This system...
Kairos Pharma and Huntsman Cancer Institute for ENV105 Phase 2 Trial
Kairos Pharma (NYSE American: KAPA) is expanding its Phase 2 clinical trial for ENV105, a drug targeting castrate-resistant prostate...
Allostem™ Shows Positive One-Year Results for Type 2 Diabetes
Creative Medical Technology Holdings, Inc. (CELZ) announced positive one-year follow-up data from a pilot study of CELZ-201 (AlloStem™) in...
Positive INB-100 Phase 1 Leukemia Trial Results Reported by in8bio
IN8bio’s Phase 1 trial of INB-100, a gamma-delta T cell therapy for complex leukemias like AML, has shown promising...
Corbus Pharmaceuticals Announces Clinical Data for CRB-701
Corbus Pharmaceuticals announced that an abstract for its first-in-human dose-escalation clinical study of CRB-701 (SYS6002) for advanced solid tumors...
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury
Lineage Cell Therapeutics has launched the DOSED clinical study to evaluate the safety and effectiveness of a new spinal...
Voyager Provides Update on SOD1 ALS Gene Therapy Program
Voyager Therapeutics is halting development of its SOD1 ALS gene therapy, VY9323, after three-month primate data revealed an off-target...
Dr. Sándor Nardai Leads Algernon Phase 2a DMT Stroke Study
Algernon Pharmaceuticals’ subsidiary, Algernon NeuroScience, has appointed Dr. Sándor Nardai as the Principal Investigator for its Phase 2a DMT...